Clinical trials: High-risk Prostate Cancer
Prostatic Neoplasms
Adjuvant Leuprolide With or Without Docetaxel in High Risk Prostate Cancer After Radical Prostatectomy
This is a prospective, multicenter, open-label, randomized phase III study in participants at high risk of recurrent prostate cancer after radical prostatectomy.
- Trial name
- NCT00283062
- Testing
- Docetaxel (TAXOTERE®) Chemotherapy, Leuprolide acetate ( ELIGARD®) Hormonal Therapy
- Where
- 17 sites in United States, Australia and 15 more
- Volunteers
- 228 people
- Sponsor
- Sanofi
Prostate Cancer
18F-DCFPyL Positron Emission Tomography (PET) in Intermediate or High Risk Prostate Cancer
This is an interventional, single group assignment, prospective nonrandomized, open label Phase 2 trial designed to evaluate 18F-DCFPyL PET imaging in men diagnosed with prostate cancer with increasing prostate-specific antigen…
- Trial name
- NCT04727736
- Testing
- 18F-DCFPyL
- Where
- United States
- Volunteers
- 47 people
- Sponsor
- Ashok Muthukrishnan
Prostate Cancer
Rituximab Neoadjuvant Therapy in Patients With Prostate Cancer Scheduled to Undergo Radical Prostatectomy
There is now substantial evidence that B cells are recruited into prostate cancers by CXCL13 released by the tumor cells. B cells release lymphotoxin which drives malignant cell proliferation through the NFkB pathway.
- Trial name
- NCT01804712
- Testing
- rituximab
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Christopher Kane
Prostate Cancer
Radiation Therapy in Treating Patients With Stage II Prostate Cancer
RATIONALE: Specialized radiation therapy that delivers a high dose of radiation directly to the tumor may kill more tumor cells and cause less damage to normal tissue.
- Trial name
- NCT00033631
- Testing
- 70.2 Gy 3D-CRT/IMRT, 79.2 Gy 3D-CRT/IMRT
- Where
- 86 sites in United States, Canada
- Volunteers
- 1,534 people
- Sponsor
- Radiation Therapy Oncology Group
Prostate Cancer
177Lu Radiolabeled Monoclonal Antibody HuJ591 (177Lu-J591) and Ketoconazole in Patients With Prostate Cancer
The purpose of this study is to test the effectiveness of the experimental drug, 177Lu-J591 in combination with ketoconazole and hydrocortisone against prostate cancer.
- Trial name
- NCT00859781
- Testing
- 177Lu-J591, Ketoconazole, Hydrocortisone
- Where
- 9 sites in United States
- Volunteers
- 55 people
- Sponsor
- Weill Medical College of Cornell University
Prostate Cancer
High Resolution MRI Study for Prostate Cancer
This high resolution MRI (hrMRI), along with stand MRI (sMRI) will be obtained at baseline and again in approximately 1 year in patients on prostate cancer active surveillance.
- Trial name
- NCT03292874
- Testing
- high resolution MRI (hrMRI)
- Where
- United States
- Volunteers
- 64 people
- Sponsor
- Cedars-Sinai Medical Center
Prostatic Neoplasms, Genital Neoplasms, Male
High Resolution, 18F-PSMA PET-MRI Before Prostate Cancer HIFU or Radical Prostatectomy
This prospective trial aims to determine if enhanced prostate imaging using two novel imaging technologies (high resolution DWI and 18F-PSMA PET-MRI) will detect prostate cancers not seen on standard multiparametric prostate MRI…
- Conditions
- Prostatic Neoplasms, Genital Neoplasms, Male, Urogenital Neoplasms, Neoplasms by Site
- Trial name
- NCT04461509
- Testing
- 18F-PSMA
- Where
- United States
- Volunteers
- 62 people
- Sponsor
- Alessandro D'Agnolo
Prostatic Hyperplasia
Study of Polyphenon E in Men With High-grade Prostatic Intraepithelial Neoplasia
The purpose of this study was to determine whether the daily consumption of decaffeinated green tea catechins (Polyphenon E®) for 1 year reduces the rate of progression to prostate cancer (PCa) in men diagnosed with HGPIN or…
- Trial name
- NCT00596011
- Testing
- Polyphenon E
- Where
- 10 sites in United States
- Volunteers
- 97 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Prostate Cancer
Eflornithine in Treating Patients At High Risk of Developing Prostate Cancer
RATIONALE: Chemoprevention therapy is the use of certain drugs to try to prevent the development of cancer. The use of eflornithine (DMFO) may be an effective way to prevent the development of prostate cancer.
- Trial name
- NCT00006101
- Testing
- eflornithine
- Where
- United States
- Volunteers
- 76 people
- Sponsor
- Thomas E. Ahlering
Prostate Cancer
Postoperative Radiation Therapy, Hormonal Therapy and Concurrent Docetaxel for High Risk Pathologic Prostate Cancer
Following a radical prostatectomy and lymph node sampling, eligible patients will undergo post-operative radiation therapy, concurrent weekly docetaxel chemotherapy , and hormonal therapy (Casodex daily and Zoladex every 3 months…
- Trial name
- NCT00669162
- Testing
- Docetaxel, Radiation Therapy, Casodex and Zoladex (or Lupron)
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- University of Kansas Medical Center
Prostate Cancer
Apalutamide and Leuprolide in Intermediate and High-risk Prostate Cancer
This is a research study to test an investigational drug (Not FDA approved), Apalutamide given in combination with Leuprolide acetate (FDA approved) in men diagnosed with high-risk prostate cancer who have already selected to…
- Trial name
- NCT02770391
- Testing
- Leuprolide acetate, Apalutamide, Radical prostatectomy
- Where
- United States
- Volunteers
- 54 people
- Sponsor
- Case Comprehensive Cancer Center
Prostate Cancer
Hormone Suppression and Radiation Therapy for 6 Months With/Without Docetaxel for High Risk Prostate Cancer
This randomized study is looking at the benefits of using docetaxel (chemotherapy) added to one of the standard treatments (radiation and hormones) for men with high-risk prostate cancer.
- Trial name
- NCT00116142
- Testing
- Docetaxel, Androgen Hormonal Suppression and Radiation, Androgen Suppression Therapy and Radiation Therapy
- Where
- United States
- Volunteers
- 350 people
- Sponsor
- Dana-Farber Cancer Institute
Prostate Cancer
Feasibility Trial Of Image Guided External Beam Radiotherapy With Or Without High Dose Rate Brachytherapy Boost In Men With Intermediate-Risk Prostate Cancer
This research is being done because investigators involved in this study would like to compare image guided external beam radiation therapy (IGRT) to IGRT plus HDR brachytherapy boost to see which treatment is better and what the…
- Trial name
- NCT01982786
- Testing
- Image guided external beam radiotherapy with or without brachytherapy boost, Brachytherapy
- Where
- 9 sites in Canada
- Volunteers
- 57 people
- Sponsor
- Canadian Cancer Trials Group
Prostate Cancer
Radiation Therapy in Treating Patients With Stage II or Stage III Prostate Cancer
RATIONALE: Radiation therapy uses high-energy x-rays and other sources to damage tumor cells. Internal radiation therapy uses radioactive material placed directly into or near a tumor to kill tumor cells.
- Trial name
- NCT00091390
- Testing
- High Dose brachytherapy boost, External beam radiotherapy
- Where
- 12 sites in United States
- Volunteers
- 129 people
- Sponsor
- Radiation Therapy Oncology Group
Prostate
Olaparib in Men With High-Risk Biochemically-Recurrent Prostate Cancer Following Radical Prostatectomy, With Integrated Biomarker Analysis
Olaparib has demonstrated preliminary efficacy in metastatic castration-resistant prostate cancer. In a trial of 49 evaluable patients treated with olaparib, 11 / 49 experienced a PSA response, and every patient with a…
- Trial name
- NCT03047135
- Testing
- Olaparib
- Where
- 4 sites in United States
- Volunteers
- 51 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins